Oncology
0 drugs are in development for Non-small Cell Lung Cancer Stage III.
- Companies
- 0
- Clinical trials
- 6
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Non-small Cell Lung Cancer Stage III pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
About this indication
Non-small Cell Lung Cancer Stage III context
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung (D002289)
Narrower concept of MeSH descriptor Non-Small Cell Lung Cancer
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
Frequently asked questions
How many clinical trials target Non-small Cell Lung Cancer Stage III?
There are 6 clinical trials targeting Non-small Cell Lung Cancer Stage III tracked by BioSniper.
What is the prevalence of Non-small Cell Lung Cancer Stage III?
The estimated prevalence of Non-small Cell Lung Cancer Stage III is approximately 75.0 per 100,000 population.